Ion Beam Applications SA
XBRU:IBAB
Ion Beam Applications SA
Ion Beam Applications SA engages in the design, manufacture, and marketing of cancer treatment and diagnosis equipment. The company is headquartered in Louvain-La-Neuve, Brabant-Wallon. IBA is also active in the sterilization and ionization field. The firm operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.
Ion Beam Applications SA engages in the design, manufacture, and marketing of cancer treatment and diagnosis equipment. The company is headquartered in Louvain-La-Neuve, Brabant-Wallon. IBA is also active in the sterilization and ionization field. The firm operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.
Guidance Confirmed: Management remains fully confident in meeting the full-year EBIT target of at least EUR 25 million, supported by controlled operating expenses and positive contributions from Proton Therapy.
Order Intake Growth: Equipment order intake reached EUR 195 million, up EUR 11 million year-on-year, with strong momentum in IBA Technologies and Radiopharma solutions.
Stable Backlog: Equipment and services backlog stands at EUR 1.3 billion, slightly down EUR 0.1 billion from last year but considered stable after strong conversion in H1.
Refinancing Secured: IBA closed a new EUR 135 million financing package to enhance balance sheet flexibility and support growth, with EUR 61 million drawn and EUR 74 million still available.
Working Capital Headwinds: Net financial position is EUR 60 million, impacted by customer delays on large projects in Spain and China; improvement expected from December 2025.
Proton Therapy Milestone: Proton Therapy is now contributing positive EBIT, seen as a key milestone from scaling activities and favorable project mix.
Regional Variability: Continued strength in APAC and active US pipeline, but dosimetry faces headwinds in the US and China due to competition.
